Johnson and Johnson has faced more major lawsuits than almost any other company in American corporate history. The Johnson and Johnson lawsuit history spans baby powder, opioids, antipsychotic drugs, and defective hip implants, totaling tens of billions of dollars in settlements and verdicts.
This isn’t ancient history. Many of these cases are still active in 2026.
If you used J&J products, were diagnosed with cancer, or know someone harmed by one of their products, this guide breaks down every major case, who got paid, and what options remain.
One number stands out before we go further: over 100,000 lawsuits have been filed against Johnson and Johnson related to talcum powder alone. That’s the scale of what we’re dealing with.
Johnson and Johnson Lawsuit History: How It All Started
Johnson and Johnson’s legal troubles did not appear overnight. The company spent more than a century building a trusted brand before cracks in its safety record began showing publicly in the 1980s and 1990s.
The earliest major crisis came in 1982, when seven people died after taking cyanide-laced Tylenol capsules in Chicago. J&J’s response, pulling 31 million bottles off shelves at a cost exceeding $100 million, became a case study in corporate crisis management. No lawsuit history starts without this event.
By the late 1990s, internal studies had begun linking talc-based products to ovarian cancer. Documents later obtained through litigation showed that J&J executives were aware of potential asbestos contamination in talc mines for decades.
The first talc-related lawsuit went to trial in 2013. By the mid-2010s, the floodgates had opened. Verdicts started coming in against the company, some reaching hundreds of millions of dollars per case.
| Decade | Legal Milestone |
|---|---|
| 1980s | Tylenol tampering crisis |
| 1990s | Early internal asbestos/talc studies surface |
| 2000s | DePuy hip implant defect problems emerge |
| 2010s | First talc cancer verdicts; Risperdal damages; opioid cases |
| 2020s | Bankruptcy attempts, mass tort MDL consolidation, settlement negotiations |
The company’s legal exposure grew with each decade. What started as product safety questions became multi-billion dollar litigation.
Johnson and Johnson Current Lawsuits 2026: What’s Active Right Now
As of 2026, Johnson and Johnson is still fighting or settling claims across several major categories. The talc litigation remains the largest and most contested.
J&J’s third attempt to resolve talc claims through bankruptcy was rejected by courts. That means tens of thousands of lawsuits are back in active litigation as of 2025 and into 2026.
The opioid settlements have largely been paid out or are in final distribution phases. Risperdal claims are mostly resolved. DePuy hip implant cases have wound down but a small number remain pending.
Active in 2026:
- Talc/baby powder ovarian cancer lawsuits (largest active group)
- Talc/baby powder mesothelioma claims
- Remaining DePuy hip implant cases
- Pharmaceutical product liability cases related to newer J&J drugs
- State attorney general actions related to opioid marketing
The talc MDL (Multidistrict Litigation 2738) remains the centerpiece of 2026 activity. It was consolidated in the U.S. District Court for the District of New Jersey.
Key Takeaway: The Johnson and Johnson lawsuit history is not over. Talc litigation is the dominant active front in 2026, with tens of thousands of claims still unresolved.
The J&J Talcum Powder Lawsuit Explained
The J&J talcum powder lawsuit is the largest and most consequential product liability battle in the company’s history. The core claim is that Johnson’s Baby Powder and Shower to Shower products contained asbestos-contaminated talc, causing ovarian cancer and mesothelioma in users.
Talc and asbestos are naturally occurring minerals often found in the same geological formations. Plaintiffs argued that J&J knew its talc supply was contaminated but continued selling the products for decades.
Internal company documents, made public through litigation, showed communications dating back to the 1970s discussing asbestos traces in talc. This evidence became the backbone of thousands of cases.
J&J stopped selling talc-based Baby Powder in the United States and Canada in 2020, citing “misinformation” and declining demand. Critics called it an admission disguised as a business decision.
| Claim Type | Primary Diagnosis | Estimated Cases Filed |
|---|---|---|
| Ovarian Cancer | Ovarian cancer from perineal talc use | 60,000+ |
| Mesothelioma | Asbestos-related cancer from inhalation | 10,000+ |
| Other Cancer | Various talc-related claims | Several thousand |
The first major verdict came in 2016, when a Missouri jury awarded $72 million to the family of Jackie Fox, a woman who died of ovarian cancer after decades of talc use. That case was later overturned on jurisdictional grounds, but it triggered a wave of similar trials.
Johnson and Johnson Baby Powder Cancer Lawsuit: Key Facts
The Johnson and Johnson baby powder cancer lawsuit connects the company’s most iconic product to some of the most serious cancers people face. Ovarian cancer is the primary diagnosis at the center of these claims.
Women who used Johnson’s Baby Powder or Shower to Shower powder in the genital area for personal hygiene are the primary claimants. Studies published in peer-reviewed journals suggested that talc particles could travel through the reproductive system and trigger inflammatory responses linked to cancer.
J&J disputed this science throughout litigation. The company pointed to studies it said showed no link. However, a 2018 Reuters investigative report found that J&J had known for decades that its talc sometimes tested positive for small amounts of asbestos.
Key facts about the baby powder cancer lawsuit:
- Products at issue: Johnson’s Baby Powder, Shower to Shower body powder
- Primary cancer claimed: Ovarian cancer, fallopian tube cancer
- Secondary cancer claimed: Mesothelioma (from asbestos in talc)
- Time period of use: Claims involve use from the 1960s through 2020
- Jury verdicts obtained: Multiple verdicts exceeding $100 million each before appeals
- Largest single verdict: $4.69 billion awarded by a Missouri jury in 2018 to 22 women (later reduced on appeal)
The $4.69 billion verdict in July 2018 was one of the largest product liability awards in U.S. history. A Missouri appeals court later cut it to $2.12 billion. J&J appealed further, and the case worked its way through multiple court levels.
Key Takeaway: The baby powder cancer lawsuit produced some of the largest consumer product verdicts in history, and the underlying science dispute has been central to J&J’s legal strategy across all talc cases.
Johnson and Johnson Asbestos Lawsuit: The Contamination Claims
The Johnson and Johnson asbestos lawsuit centers on a specific claim: that J&J’s talc was contaminated with asbestos, a known human carcinogen, and that the company failed to warn the public.
Asbestos causes mesothelioma, a rare and aggressive cancer affecting the lining of the lungs, abdomen, or heart. Mesothelioma cases tied to talc products represent a distinct legal track from the ovarian cancer claims.
The legal basis is product liability: J&J allegedly sold a product it knew or should have known was dangerous without adequate warning. Internal documents showed that the company tested its talc and sometimes found trace amounts of asbestos but did not always disclose those findings publicly or to regulators.
What makes asbestos claims different from ovarian cancer claims:
- Asbestos exposure can come from inhaling baby powder during use
- Workers at J&J manufacturing facilities also filed asbestos exposure claims
- Mesothelioma has a latency period of 20 to 50 years, meaning people diagnosed today may have been exposed decades ago
- Asbestos claims are generally treated as a separate litigation track with different medical evidence requirements
The FDA conducted tests in 2019 that found asbestos in Johnson’s Baby Powder samples. J&J recalled approximately 33,000 bottles at that time but continued disputing the broader contamination allegations.
| Lawsuit Track | Primary Illness | Key Evidence Used |
|---|---|---|
| Asbestos/Talc | Mesothelioma | Inhalation studies, product testing, internal memos |
| Perineal Talc | Ovarian cancer | Usage history, epidemiological studies, internal documents |
J&J Opioid Settlement: What the Company Paid and Why
The J&J opioid settlement placed the company among the pharmaceutical companies held accountable for America’s opioid epidemic. J&J manufactured and marketed opioid drugs and also supplied raw opioid ingredients to other drug makers.
In 2021, Johnson and Johnson agreed to pay $5 billion over nine years as part of a nationwide opioid settlement with 46 states, the District of Columbia, and several territories. The money was directed toward opioid treatment, recovery programs, and addiction services.
J&J’s role differed from companies like Purdue Pharma. J&J made opioids including Duragesic (fentanyl patches) and Nucynta. Its subsidiary Tasmanian Alkaloids cultivated opium poppies in Tasmania to supply raw ingredients to U.S. drug manufacturers.
Prosecutors argued J&J marketed opioids aggressively and minimized addiction risks. J&J disputed that characterization but settled to avoid prolonged litigation.
Opioid settlement breakdown:
- Total settlement: $5 billion over 9 years
- First-year payment: $1.5 billion
- Use of funds: Opioid abatement, treatment, recovery programs
- Participating parties: 46 states, D.C., and U.S. territories
- J&J admission: None; settlement included no admission of wrongdoing
States received allocations based on population and opioid impact formulas. Individual patients did not receive direct payments from this settlement. The money went to state governments.
Johnson and Johnson Risperdal Lawsuit: Billions in Damages
The Johnson and Johnson Risperdal lawsuit is one of the most disturbing chapters in the company’s pharmaceutical history. Risperdal is an antipsychotic drug approved for schizophrenia and bipolar disorder in adults.
The allegations: J&J marketed Risperdal for unapproved uses, including in children and elderly dementia patients, without adequate safety warnings. A serious side effect in young males was gynecomastia, the development of breast tissue.
Thousands of young men and boys filed suit claiming that Risperdal caused them to grow breast tissue. Many required surgery to address the condition.
Key Risperdal verdicts and settlements:
- In 2013, J&J paid $2.2 billion to resolve federal criminal and civil allegations related to Risperdal marketing
- Pennsylvania juries awarded large verdicts in individual Risperdal cases through the 2010s
- In 2019, a Philadelphia jury awarded $8 billion in punitive damages to a single plaintiff, Nicholas Murray. A judge later reduced the award to $6.8 million for punitive damages
- J&J ultimately settled thousands of individual Risperdal claims
The $2.2 billion resolution in 2013 included J&J subsidiary Janssen Pharmaceuticals pleading guilty to a criminal misdemeanor charge for misbranding Risperdal.
Key Takeaway: The Risperdal cases showed that J&J’s legal exposure extended well beyond consumer products into prescription drug marketing practices that resulted in criminal charges and billions in penalties.
J&J Hip Implant Recall Lawsuit: DePuy and the Metal-on-Metal Crisis
The J&J hip implant recall lawsuit stems from problems with DePuy Orthopaedics, a J&J subsidiary that made metal-on-metal hip replacement devices. These implants were recalled in 2010 after reports of premature failure and serious complications.
The primary device at issue was the ASR (Articular Surface Replacement) hip system. Metal-on-metal implants were supposed to last longer than traditional devices. Instead, they wore down and released metallic particles into patients’ bloodstreams, causing tissue damage, bone loss, and requiring painful revision surgeries.
DePuy recalled approximately 93,000 ASR devices worldwide. At the time, the recall was one of the largest medical device recalls in history.
J&J established a settlement program. By 2013, the company had set aside $2.5 billion to resolve U.S. claims. By 2016, total settlement costs for DePuy ASR claims had exceeded $4 billion globally.
DePuy hip implant lawsuit facts:
| Detail | Information |
|---|---|
| Device recalled | DePuy ASR Hip System |
| Recall date | August 2010 |
| Devices recalled | Approximately 93,000 globally |
| Settlement fund (U.S.) | $2.5 billion (initial, 2013) |
| Total global cost | Exceeded $4 billion |
| Key complication | Metallosis, tissue necrosis, premature device failure |
Most DePuy claims have been resolved. A small number of cases involving later-generation DePuy devices remain in litigation as of 2026.
Johnson and Johnson Bankruptcy Filing: Why They Used Chapter 11
Johnson and Johnson’s bankruptcy filing strategy is one of the most controversial legal maneuvers in recent corporate history. J&J did not file for bankruptcy itself. Instead, it used a legal tactic called the “Texas Two-Step.”
Here’s how it worked: J&J created a new subsidiary called LTL Management LLC in 2021 and transferred its talc liabilities to that entity. LTL then filed for Chapter 11 bankruptcy protection. This move was designed to pause all talc lawsuits while a bankruptcy settlement was negotiated.
The strategy drew immediate backlash from plaintiff attorneys and consumer advocates. Critics called it an abuse of the bankruptcy system, allowing a profitable company to use bankruptcy protections designed for genuinely insolvent businesses.
Why J&J used this approach:
- J&J’s parent company was financially healthy with billions in annual revenue
- Bankruptcy courts can consolidate all claims and impose a settlement trust
- A successful bankruptcy resolution could cap J&J’s total talc liability
- Jury verdicts in individual trials had been unpredictable and sometimes enormous
The Third Circuit Court of Appeals rejected LTL Management’s first bankruptcy attempt in January 2023, ruling that LTL was not in financial distress. J&J filed again, and that second attempt was also rejected.
J&J LTL Management Bankruptcy Update: Where Things Stand in 2026
The J&J LTL Management bankruptcy situation reached a turning point in 2024 and set the stage for where things stand going into 2026. After two failed bankruptcy attempts, J&J proposed a third approach.
In May 2024, J&J announced a revised plan to pay approximately $6.5 to $8 billion over 25 years to resolve roughly 62,000 talc claims. The company sought to restructure the settlement proposal and again funnel it through bankruptcy court to bind all claimants.
Federal courts have continued to scrutinize whether this approach is legally valid. As of the start of 2026, the bankruptcy route remains contested in courts, and the final resolution is not yet settled.
What this means practically:
- If the bankruptcy settlement is approved, claimants would receive payments from a trust fund over many years
- If it’s rejected again, individual lawsuits resume and cases head back to trial
- The amount per claimant would depend on which outcome prevails and how many approved claimants share the total fund
Current LTL/Talc Status in 2026:
| Status Element | Detail |
|---|---|
| Proposed settlement fund | $6.5 to $8 billion |
| Repayment term | 25 years |
| Estimated affected claimants | 62,000+ |
| Court status | Continued litigation over validity of bankruptcy approach |
| Previous bankruptcy rejections | Two (January 2023, 2024) |
This is the most important ongoing development in the entire Johnson and Johnson lawsuit history for anyone currently holding a claim.
Key Takeaway: J&J’s LTL bankruptcy strategy has failed twice and remains under legal challenge in 2026, meaning tens of thousands of talc claimants are still waiting to see whether they’ll receive payment through a trust or through individual lawsuits.
Johnson and Johnson Settlement Timeline: Case by Case Breakdown
The Johnson and Johnson settlement timeline shows how the company has resolved cases across multiple categories over four decades. Some settlements came quickly. Others took years of trials, appeals, and negotiations.
Understanding the timeline helps claimants gauge how long their own cases might take and what stage of resolution different lawsuit types are in.
Complete J&J Settlement Timeline:
| Year | Lawsuit Type | Outcome |
|---|---|---|
| 1982 | Tylenol tampering | J&J absorbed product recall costs; no mass tort |
| 2013 | Risperdal (federal) | $2.2 billion criminal/civil resolution |
| 2013 | DePuy hip (U.S.) | $2.5 billion settlement fund established |
| 2016 | DePuy hip (global) | Costs exceeded $4 billion total |
| 2016 | First major talc verdict | $72 million (Jackie Fox; later overturned) |
| 2018 | Talc multi-plaintiff | $4.69 billion verdict (reduced to $2.12B on appeal) |
| 2021 | Opioid nationwide | $5 billion settlement over 9 years |
| 2021 | LTL bankruptcy attempt 1 | Filed October 2021 |
| 2023 | LTL bankruptcy rejection 1 | Third Circuit rejects; January 2023 |
| 2024 | Revised settlement proposal | $6.5 to $8 billion proposed; contested |
| 2026 | Ongoing | Talc MDL litigation continues; status unresolved |
The opioid resolution was the fastest major settlement, reached relatively quickly compared to the talc litigation. DePuy took roughly six years from recall to substantial settlement. Risperdal federal charges took about a decade from the conduct to resolution.
The talc litigation has now been active in courts for over a decade with no final resolution as of 2026.
J&J Talc Settlement Amount: How Much Has Been Paid Out
The J&J talc settlement amount is the most searched financial question connected to this litigation, and the honest answer is: not as much as many expected, and not yet as much as many are owed.
J&J has not executed a global talc settlement as of early 2026. The company paid individual verdicts and some private settlements, but a comprehensive resolution covering all 60,000-plus claimants does not yet exist.
What has been paid in talc cases so far:
- Individual trial verdicts: Multiple cases settled privately on confidential terms after large initial verdicts
- Estimated total paid in resolved individual talc cases: Several hundred million dollars through private settlements
- Proposed future fund: $6.5 to $8 billion (if the current plan is approved)
- Average proposed payment per claimant: If 62,000 claimants share $6.5 billion, that’s approximately $100,000 per claimant before attorneys’ fees
The actual amount per person varies widely based on:
- Severity of illness (ovarian cancer vs. mesothelioma vs. other)
- Duration of product use
- Ability to prove product use through purchase records or testimony
- Medical documentation of diagnosis
Mesothelioma claimants have historically received larger individual settlements than ovarian cancer claimants due to the severity and rarity of the disease.
Johnson and Johnson Lawsuit Payout Per Person: What Claimants Actually Received
The Johnson and Johnson lawsuit payout per person varies enormously depending on which lawsuit category you’re in and how your case was resolved.
There is no single flat payment amount. Each case is evaluated individually. Here’s what real claimants have received across different lawsuit types:
Payout ranges by lawsuit type:
| Lawsuit Category | Reported Settlement Range Per Person |
|---|---|
| Talc ovarian cancer | $100,000 to $500,000 (private settlements; estimates) |
| Talc mesothelioma | $500,000 to several million (higher due to severity) |
| DePuy hip implant | Average approximately $250,000 (per settlement program data) |
| Risperdal gynecomastia | Varied; some cases settled for six figures |
| Opioid (individual) | Opioid settlement went to states, not individuals directly |
These are estimates and reported ranges. Actual private settlement amounts are often confidential.
Attorneys’ fees in these cases typically run 33% to 40% of any recovery. A $300,000 settlement might net a claimant $180,000 to $200,000 after fees and costs.
Your individual payout also depends on your attorney’s negotiating position, the strength of your medical evidence, and whether your case goes to trial or settles early. Cases that survive to trial verdicts have sometimes yielded far more but also carry the risk of appeals that reduce awards significantly.
Key Takeaway: Payout amounts for Johnson and Johnson lawsuits range from tens of thousands to several million dollars depending on the case type, severity of injury, and how the case is resolved.
J&J Consumer Product Liability Cases: Beyond Baby Powder
The J&J consumer product liability cases extend beyond talc to include a range of products and situations most people never connect to the company. J&J is one of the world’s largest consumer health companies, and its product portfolio creates broad liability exposure.
Products you might not realize fall under J&J’s legal history:
- Neutrogena sunscreen: In 2021, J&J recalled several Neutrogena and Aveeno aerosol sunscreen products after testing found benzene, a known carcinogen, in some samples. Consumer lawsuits followed.
- Tylenol during pregnancy: Ongoing litigation alleges that acetaminophen use during pregnancy is linked to autism and ADHD in children. J&J and store-brand acetaminophen makers face these claims, though this litigation is at an earlier stage.
- Contact lens solutions: J&J’s Acuvue-related products and contact lens solutions have faced isolated product liability complaints over the years.
- Johnson’s Baby Products beyond powder: Shampoo formulation concerns led to reformulations in earlier years following consumer pressure.
The Tylenol-autism litigation is worth watching. A federal judge in New York is presiding over an MDL involving acetaminophen pregnancy claims. As of 2026, this litigation is still in early pretrial stages, but it could become the next major J&J product liability battleground.
Who Qualifies for Johnson and Johnson Lawsuit Compensation
Who qualifies for Johnson and Johnson lawsuit compensation depends entirely on which lawsuit you’re looking at. Each case has different eligibility requirements.
For the talc/baby powder cases, general eligibility criteria include:
- You used Johnson’s Baby Powder or Shower to Shower powder, typically for years or decades
- You were diagnosed with ovarian cancer, fallopian tube cancer, or mesothelioma
- There is a reasonable connection between your product use and your diagnosis
- You or a qualifying family member have medical records documenting the diagnosis
For mesothelioma claims, the requirements are similar but focus on asbestos exposure through talc inhalation rather than perineal use.
For DePuy hip implant cases, you must:
- Have received a DePuy ASR hip replacement device
- Have experienced complications including early device failure, metallosis, pain, or revision surgery
- Have surgery records and medical documentation of the device and complications
For Risperdal cases, eligible claimants are typically males who were prescribed Risperdal and developed gynecomastia (breast tissue growth) as a result.
Eligibility quick reference:
| Case Type | Key Eligibility Requirement |
|---|---|
| Talc ovarian cancer | Used product + ovarian/fallopian cancer diagnosis |
| Talc mesothelioma | Used product + mesothelioma diagnosis |
| DePuy hip | Received ASR device + experienced complications |
| Risperdal | Took drug as minor or adult + developed gynecomastia |
| Opioid (individual) | Not applicable; settlement went to states |
Statutes of limitations apply. In most states, you have 2 to 3 years from the date you discovered your injury or diagnosis to file a claim. Some states have different rules for latent injuries like cancer.
How to File a Johnson and Johnson Claim in 2026
Filing a Johnson and Johnson claim in 2026 starts with one step: contact a mass tort attorney who handles J&J product liability cases. Do not try to file directly with a court on your own.
Here is what the process typically looks like:
Step 1: Gather your documentation.
You need medical records showing your diagnosis, evidence of product use (receipts, photographs, family testimony), and prescription records if your claim involves a pharmaceutical product.
Step 2: Find an attorney who handles J&J cases.
Most mass tort attorneys take these cases on contingency, meaning you pay nothing upfront. Their fee comes from your settlement or verdict.
Step 3: Your attorney evaluates your claim.
They’ll assess whether your diagnosis and product use meet the criteria, review your medical records, and determine which lawsuit category fits your situation.
Step 4: Your case is filed.
Depending on your location and case type, it may be filed in federal court as part of an MDL, in your state’s court system, or joined to an existing consolidated proceeding.
Step 5: Discovery, negotiation, or trial.
Most cases settle before trial. Your attorney negotiates on your behalf. If a settlement isn’t reached, your case may go to trial.
Important 2026 timing notes:
- If you have a talc/cancer claim and have not yet filed, check your state’s statute of limitations immediately
- The current bankruptcy proceedings could affect how and where claims are filed
- Mesothelioma claimants may have faster-track options due to the severity of the disease
Key Takeaway: Filing a J&J claim in 2026 requires a qualified mass tort attorney, proper medical documentation, and an understanding of your state’s deadlines, especially given the ongoing bankruptcy proceedings that affect how claims are processed.
Frequently Asked Questions
What is the Johnson and Johnson lawsuit history about?
The Johnson and Johnson lawsuit history covers decades of product liability, pharmaceutical misconduct, and consumer safety cases.
Major categories include talcum powder cancer lawsuits, opioid settlement obligations, Risperdal drug marketing fraud, and DePuy hip implant defects.
Combined, these cases have cost J&J tens of billions of dollars in verdicts and settlements.
How much money did Johnson and Johnson pay in lawsuits?
Johnson and Johnson has paid well over $15 billion in lawsuits, settlements, and fines across all major case categories.
The $5 billion opioid settlement, the $2.2 billion Risperdal resolution, and over $4 billion in DePuy hip cases account for the bulk of confirmed payments.
Talc settlements are still pending a final resolution that could add another $6.5 to $8 billion if the current proposal is approved.
Who qualifies for the Johnson and Johnson baby powder lawsuit in 2026?
Women who used Johnson’s Baby Powder or Shower to Shower powder and were diagnosed with ovarian cancer or mesothelioma are the primary eligible claimants in 2026.
You must have medical records documenting your diagnosis and be able to establish a history of product use.
Consulting a mass tort attorney is the fastest way to determine if your situation meets the filing criteria.
Is the Johnson and Johnson talc lawsuit still open in 2026?
Yes, the Johnson and Johnson talc lawsuit is still open and actively contested in 2026.
J&J’s third bankruptcy settlement proposal is being reviewed by courts, and thousands of individual claims remain unresolved.
New filings are still being accepted in most jurisdictions, depending on state-specific statute of limitations rules.
How long does it take to receive a Johnson and Johnson lawsuit settlement?
Settlement timelines for J&J cases vary from one to several years depending on case type, complexity, and court proceedings.
DePuy hip cases took roughly four to six years from filing to payment for many claimants.
Talc cases have been in litigation for over a decade, and final payouts may not arrive until the bankruptcy proceedings are fully resolved, which could extend into 2027 or beyond.
What You Should Do Right Now
The Johnson and Johnson lawsuit history is still being written. The talc litigation alone involves more than 60,000 people waiting for resolution, and 2026 is a pivotal year for whether that happens through a bankruptcy trust or through individual trials.
If you were diagnosed with ovarian cancer, mesothelioma, or another qualifying condition and used J&J products, your statute of limitations clock is running. Waiting is the one thing that can permanently close the door on your claim.
Talk to a mass tort attorney who handles J&J cases. Get your medical records organized. Check your state’s deadline. Your window may be shorter than you think.
